Reuters logo
BRIEF-Sangui Biotech International H1 revenues up at $35,508
February 24, 2017 / 2:46 PM / 7 months ago

BRIEF-Sangui Biotech International H1 revenues up at $35,508

Feb 24 (Reuters) - Sangui Biotech International Inc :

* H1 revenues from royalty income and product sales of $35,508. In the same period of previous year comparable revenue amounted to $26,856

* Operating loss of first half year decreased compared to prior year by $30,975 to $218,615

* For full year 2017, however, company is still expecting increase in sales of granulox and corresponding royalty revenues Source text for Eikon: Further company coverage: (Gdynia Newsroom)

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below